Office of the Scientific Director - The Intramural Research Program of the National Institute on Drug Abuse

Skip Navigation

Office of the Scientific Director

Overview

The Office of the Scientific Director provides scientific, program, and administrative leadership for the Division of Intramural Research; promotes an environment conducive to productive research; and coordinates activities, establishes priorities, and analyzes and evaluates progress.

Scientific Director: Antonello Bonci, M.D. on-site page link

Deputy Scientific Director: Amy Hauck Newman, Ph.D.on-site page link

Chief of Staff: Michelle Leff, M.D. ( CAPT, USPHS) Email

Regulatory Affairs Officer: Leslie Premo (MPP, MS) Email

Director, Office of Education and Career Development: Stephen Heishman, Ph.D. on-site page link

Associate Director for Diversity and Outreach: Michelle L. Jobes, Ph.D. on-site page link


Animal Care and Use Program

The Animal Care and Use Program of the Office of the Director is responsible for directing animal care and use at the Intramural Research Program of the National Institute on Drug Abuse, and for providing animal research support services to the various branches of the intramural research program. The Program also provides advice, guidance, and consultative services to scientific and administrative staff of the Institute.

Animal Program Director: Kyle Stump, DVM, DACLAM Email

 

Designer Drug Research Unit

The main goal of the DDRU is to collect, analyze and disseminate the most up-to-date information about the pharmacology and toxicology of newly-emerging designer drugs of abuse, more formally known as new psychoactive substances (NPS).  NPS include synthetic drugs which mimic the effects of stimulants (e.g., “bath salts”), cannabinoids (e.g., “spice”), hallucinogens (e.g., “NBOMes”) and opioids (e.g., fentanyl analogs).  These substances are specifically engineered to circumvent drug control laws and are often misused as a means to avoid detection of drug use.

Chief: Michael H. Baumann, Ph.D. Email

Topics of investigation include:

  • Pharmacology of newly-emerging designer drugs of abuse, such as “bath salts” stimulants and “K2/Spice” cannabinoids
  • Structure-activity relationships for ligands interacting at monoamine transporter proteins
  • Mechanisms underlying neurotoxic effects of stimulant drugs of abuse


Related Information...

Health and Human Services Logo National Institute on Drug Abuse Logo


The National Institute on Drug Abuse (NIDA), is part of the National Institutes of Health (NIH), the principal biomedical and behavioral research agency of the United States Government. NIH is a component of the U.S. Department of Health and Human Services.

PDF documents require the free Adobe Reader. Microsoft Word documents require the free Microsoft Word viewer. Microsoft PowerPoint documents require the free Microsoft PowerPoint viewer. Flash content requires the free Adobe Flash Player.